Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NS-089/NCNP-02 in Duchenne Muscular Dystrophy
NCT04129294Phase 2Completed
- Sponsor
- National Center of Neurology and Psychiatry
- Start
- Dec 2019
- Primary completion
- May 2022
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
A Phase 2 trial of brogidirsen in Duchenne muscular dystrophy (DMD), sponsored by National Center of Neurology and Psychiatry. Started Dec 2019; status: completed.
02
Drugs
brogidirsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT04129294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04129294.